6
|
Carmona-Bayonas A, Jiménez-Fonseca P, Lorenzo MLS, Ramchandani A, Martínez EA, Custodio A, Garrido M, Echavarría I, Cano JM, Barreto JEL, García TG, Manceñido FÁ, Lacalle A, Cardona MF, Mangas M, Visa L, Buxó E, Azkarate A, Díaz-Serrano A, Montes AF, Rivera F. On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry. J Natl Compr Canc Netw 2017; 14:1379-1388. [PMID: 27799509 DOI: 10.6004/jnccn.2016.0148] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2016] [Accepted: 07/21/2016] [Indexed: 11/17/2022]
Abstract
BACKGROUND There is currently no consensus regarding first-line chemotherapy for patients with advanced gastric cancer (AGC) who are ineligible to receive trastuzumab. The objective of this study was to evaluate the efficacy and tolerance of triplets versus doublets by analyzing a national gastric cancer registry. PATIENTS AND METHOD Patients with AGC treated with polychemotherapy without associating trastuzumab were included from 2008 through 2016. The effect of triplets versus doublets was compared using 3 methods: Cox proportional hazards regression, propensity score matching (PSM), and coarsened exact matching (CEM). RESULTS A total of 970 patients were recruited (doublets: n=569; triplets: n=401). In the multivariate Cox model, the use of triplets was associated with better overall survival (OS), with a hazard ratio (HR) of 0.84 (95% CI, 0.72-0.98; P=.035). After PSM, the sample contained 340 pairs. A significant increase in OS, 11.14 months (95% CI, 9.60-12.68) versus 9.60 months (95% CI, 8.44-10.75), was seen in favor of triplets (HR, 0.77; 95% CI, 0.65-0.92; stratified log-rank test, P=.004). The effect appeared to be comparable for anthracycline-based (HR, 0.78; 95% CI, 0.64-0.94) or docetaxel-based triplets (HR, 0.78; 95% CI, 0.60-1.009). The trend was similar after applying the CEM algorithm, with an HR of 0.78 (95% CI, 0.63-0.97; P=.03). Triplet therapy was viable and relative dose intensities exceeded 85%, except for cisplatin in DCX (docetaxel, cisplatin, capecitabine). Triplets had more severe toxicity overall, especially hematologic, hepatic, and mucosal adverse events. CONCLUSIONS With the limitations of a retrospective study that examines a heterogeneous set of chemotherapy regimens, we found that triplets are feasible in daily practice and are associated with a discreet benefit in efficacy at the expense of a moderate increase in toxicity.
Collapse
Affiliation(s)
- Alberto Carmona-Bayonas
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Paula Jiménez-Fonseca
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Maria Luisa Sánchez Lorenzo
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Avinash Ramchandani
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Elena Asensio Martínez
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Ana Custodio
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Marcelo Garrido
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Isabel Echavarría
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Juana María Cano
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Jose Enrique Lorenzo Barreto
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Teresa García García
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Felipe Álvarez Manceñido
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Alejandra Lacalle
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Marta Ferrer Cardona
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Monserrat Mangas
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Laura Visa
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Elvira Buxó
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Aitor Azkarate
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Asunción Díaz-Serrano
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Ana Fernández Montes
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| | - Fernando Rivera
- From Hematology and Medical Oncology Department, Hospital Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain; Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain; Medical Oncology Department, Hospital General Universitario de Elche, Alicante, Spain; Medical Oncology Department, Hospital Universitario La Paz, Madrid, Spain; Hematology and Medical Oncology Department, Hospital Universitario de Ciudad Real, Cuidad Real, Spain; Medical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain; Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain; Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Pharmacy Department, Hospital Universitario Central de Asturias, Oviedo, Spain; Medical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain; Medical Oncology Department, Hospital Universitario Parc Tauli, Sabadell, Spain; Medical Oncology Department, Hospital Galdakao-Usansolo, Usansolo, Spain; Medical Oncology Department, Hospital Universitario del Mar, Barcelona, Spain; Medical Oncology Department, Hospital Clínic, Barcelona, Spain; Medical Oncology Department, Hospital Universitario Son Espases, Mallorca, Spain; Medical Oncology Department, Hospital Universitario Doce de Octubre, Madrid, Spain; Medical Oncology Department, Complejo Hospitalario de Orense, Spain; and Medical Oncology Department, Hospital Universitario de Valdecilla, Santander, Spain
| |
Collapse
|